Consistent with the results obtained with the Syk inhibitor piceatannol, Syk siRNA knock-down leads to a significant reduction in zymosan-induced NFAT translocation, but did not affect AF-induced NFAT translocation. Here, SYK is linked to atrial fibrillation.